Search Results

CytoMed Therapeutics Limited has obtained board approval to launch, subject to certain terms and conditions, a pilot program to isolate and cryo-store peripheral blood mononuclear cells for and as a reward to loyal shareholders of CytoMed on a complimentary basis.

CytoMed Therapeutics Limited today announced that it has entered into a Heads of Agreement (HOA) with CytoMed Therapeutics China Limited company incorporated in Hong Kong and a Memorandum of Understanding (MOU) with BioNex Solutions Inc.

CytoMed Therapeutics Limited announced that the Intellectual Property Corporation of Malaysia has granted a patent for its chimeric antigen receptor gamma delta T cell technology, which targets solid and hematological tumors.

CytoMed Therapeutics Limited today announced its first half of 2023 financial results and provided clinical and corporate updates.

CytoMed Therapeutics Limited announced that it has entered into a Research Collaboration Agreement with Sengkang General Hospital Pte Ltd, a public hospital in Singapore and a member of the SingHealth group to establish proof-of-concept use of an injectable cartilage regeneration therapy that has been developed with donor-sourced, umbilical cord-derived mesenchymal stem cells to treat cartilage injury.

CytoMed Therapeutics Limited today announced it will be presenting at The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference to be held Thursday, December 7th, 2023 at the New York Athletic Club in New York City.

CytoMed Therapeutics Limited today announced that its exclusively licensed induced pluripotent stem cell (iPSC)-based technology has been granted a patent by the China National Intellectual Property Administration (CNIPA).

CytoMed Therapeutics Limited recently announced its exclusively licensed induced pluripotent stem call -based technology has been granted a patent by the China National Intellectual Property Administration.